

Contacts Media

Amsterdam +31 20 721 4133
Dublin +39 02 72 42 62 13
Milan +39 02 72 42 67 56
Paris +33 1 70 48 24 45

Brussels +31 20 721 4133
Lisbon +351 91 777 68 97
Oslo +47 41 69 59 10

Contact Investor Relations

+33 1 70 48 24 17

Lifecare transfers to Euronext Oslo Børs

- **The second transfer on Euronext Oslo Børs this year**
- **Market capitalisation of approximately NOK 317 million**



Oslo – 22 October 2024 – Euronext Oslo Børs congratulates Lifecare (ticker: LIFE), a Norwegian medtech company listed since 2018, on its transfer from Euronext Growth Oslo to Euronext Oslo Børs. This is the second transfer this year between the Oslo markets.

Lifecare develops miniaturised and implantable long-term medical sensors for continuous monitoring of glucose and other biomarkers. The company has a particular focus on diabetes, helping the more than 500 million people living with the disease today. The company is headquartered in Bergen, Norway. Its research and development activities are performed in Mainz and Reutlingen in Germany and its chemistry lab is situated in Bristol, UK.

At opening, the share price was NOK 20 per share, based on the closing price on Euronext Growth Oslo on 21 October 2024. This corresponds to an estimated market capitalisation of NOK 317 million.

Joacim Holter, CEO of Lifecare, said: "It is an important milestone for Lifecare to take the step to the regulated market Euronext Oslo Børs. On behalf of the entire organisation, I am very proud that Oslo Børs' listing committee has assessed and concluded that Lifecare meets the conditions for admission to the main market. We have a proven technology, we have focused on setting up production and we are now approaching our first product. Lifecare is now ready for the main market on Euronext Oslo Børs."



Caption: Joacim Holter, CEO of Lifecare, rang the bell this morning to celebrate the transfer to Euronext Oslo Børs. The company was welcomed by Øivind Amundsen, CEO of Euronext Oslo Børs, and Eirik Høyby Ausland, Head of Listing at Euronext Oslo Børs. (Photo: Thomas Brun | NTB)

MEDIA – mediateam@euronext.com

Oslo Cathrine Lorvik +47 41 69 59 10 oslopressoffice@euronext.com
 Segerlund

About Lifecare

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (CGM) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (NTR) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end of September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets,



simplifying access to listing for SMEs. For the latest news, go to [euronext.com](https://www.euronext.com) or follow us on Twitter (twitter.com/euronext) and LinkedIn (<https://www.linkedin.com/company/euronext>).

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

